Valuation: Lin BioScience, Inc.

Market Cap 129B 3.89B 3.54B 3.28B 2.97B 5.57B 363B 5.83B 39.66B 15.73B 196B 14.6B 14.29B 622B P/E 2024
-14.5x
P/E 2025 -23.9x
Enterprise Value 112B 3.4B 3.1B 2.87B 2.59B 4.86B 317B 5.09B 34.64B 13.74B 171B 12.75B 12.48B 543B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-22.90%
1 week-30.72%
Current month-24.84%
1 month-26.01%
3 months+27.26%
6 months+199.87%
Current year+201.01%
1 week 110
Extreme 110.00000000
179
1 month 110
Extreme 110.00000000
187
Current year 33.1
Extreme 33.1
207
1 year 24.75
Extreme 24.75
207
3 years 7
Extreme 7
207
5 years 7
Extreme 7
207
10 years 2.7
Extreme 2.7
207
Manager TitleAgeSince
Chief Executive Officer - 2016-05-31
Director of Finance/CFO 40 2022-07-24
Chief Operating Officer 45 2018-07-31
Director TitleAgeSince
Chairman 48 2016-10-12
Director/Board Member - 2024-06-26
Director/Board Member 80 2018-09-26
Change 5-day change 1-year change 3-year change Capi.($)
-22.90%-30.72%+342.59%+966.96% 3.89B
+0.72%-5.47%+30.79%+128.33% 1,204B
+1.77%-4.94%+33.77%+81.21% 643B
+1.82%-2.06%+25.93%+108.91% 501B
-0.71%-2.13%+27.04%+67.03% 378B
+2.46%-7.49%+43.94%+33.13% 327B
+0.22%-4.86%+27.01%+51.33% 285B
+1.12%-3.69%-1.35%+33.25% 270B
+1.34%-5.10%+31.50%+66.55% 237B
+1.77%+0.91%+35.69%+123.16% 207B
Average -1.27%-6.67%+59.69%+165.99% 406B
Weighted average by Cap. +1.07%-4.73%+29.55%+90.24%

Financials

2024 2025
Net sales - -
Net income -744M -22.53M -20.53M -19M -17.19M -32.24M -2.1B -33.75M -230M -91.11M -1.14B -84.52M -82.75M -3.6B -1.36B -41.25M -37.59M -34.79M -31.47M -59.04M -3.85B -61.8M -421M -167M -2.08B -155M -152M -6.6B
Net Debt -5.17B -157M -143M -132M -119M -224M -14.63B -235M -1.6B -633M -7.9B -588M -575M -25.04B -16.27B -492M -449M -415M -376M -705M -46B -738M -5.02B -1.99B -24.86B -1.85B -1.81B -78.73B
Projected Income Statement - Annual - Lin BioScience, Inc.
Logo Lin BioScience, Inc.
LIN BIOSCIENCE, INC. is a Taiwan-based company mainly engaged in the development of new pharmaceutical drugs. The Company is in the research and development and clinical trials stage. It has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.
Employees
-
Date Price Change Volume
26-11-19 NT$119.50 -22.90% 17,197,420
26-11-19 NT$155.00 -4.62% 6,781,086
26-11-18 NT$162.50 -2.40% 2,581,713
26-11-17 NT$166.50 +1.52% 3,008,437
26-11-16 NT$164.00 -7.87% 7,557,589
  1. Stock Market
  2. Stocks
  3. 6696 Stock